Home > Healthcare > Pharmaceuticals > Finished Drug Form > Lisinopril Market

Lisinopril Market Share

Report ID: GMI9455
Published Date: May 2024
Report Format: PDF

Download Free Sample

Lisinopril Market Share

The lisinopril industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.

Lisinopril Market Companies

Some of the eminent market participants operating in the lisinopril industry include:

AbbVie Inc.
Amneal Pharmaceutical, Inc.
AstraZeneca
Apotex Inc.
Aurobindo Pharma Ltd.
Bausch Health Companies, Inc.
Cipla Limited
Hikma Pharmaceutical PLC.
Lupin Limited
Merck & Co., Inc.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited
Vitaris Inc.
Zydus Lifesciences Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global lisinopril market size was valued at USD 1.5 billion in 2023 and will grow at 4.8% CAGR from 2024 to 2032, driven by the growing prevalence of cardiovascular diseases.

The tablet segment in the global market held a decent market share in 2023 and is estimated to account for USD 1.9 billion by the end of 2032, owing to their ease of usage.

U.S. lisinopril market revenue reached USD 631.4 million in 2023, and is set to grow by 2032, driven by the increasing prevalence of hypertension and cardiovascular diseases.

AbbVie Inc, Amneal Pharmaceutical, Inc, AstraZeneca, Apotex Inc, Aurobindo Pharma Ltd., Bausch Health Companies, Inc, Cipla Limited, Hikma Pharmaceutical PLC, Lupin Limited, and Merck & Co., Inc. among others.